Literature DB >> 12852718

Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials.

A H J Naber1, D J de Jong.   

Abstract

In patients with inflammatory bowel disease, assessment of disease activity is important in order to monitor and adjust therapy. In individual patients, disease evaluation is largely based on subjective symptoms. However, for disease evaluation in clinical trials, an objective and reproducible disease activity index is needed. At present, a number of activity indices are available for Crohn's disease and for ulcerative colitis. These indices may be distinguished in more subjective clinical indices, more objective endoscopic and histological indices, and in indices with combinations of both subjective and objective parameters. In the design of a new clinical trial, an appropriate disease activity index should be selected which is based on the patient selection criteria and the aims of the study.

Entities:  

Mesh:

Year:  2003        PMID: 12852718

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  14 in total

1.  Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI).

Authors:  Eyal Gal; Alex Geller; Gerald Fraser; Zohar Levi; Yaron Niv
Journal:  Dig Dis Sci       Date:  2007-11-22       Impact factor: 3.199

2.  Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease.

Authors:  Michalis Tzivras; Vassilios Koussoulas; Evangelos J Giamarellos-Bourboulis; Dimitrios Tzivras; Thomas Tsaganos; Pantelis Koutoukas; Helen Giamarellou; Athanasios Archimandritis
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis.

Authors:  Jin Young Yoon; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2013-12-19       Impact factor: 3.199

4.  Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis.

Authors:  Sami Karoui; Sonia Laz; Meriem Serghini; Norsaf Bibani; Jalel Boubaker; Azza Filali
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

5.  Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?

Authors:  Emrah Posul; Bulent Yilmaz; Gulali Aktas; Mevlut Kurt
Journal:  Wien Klin Wochenschr       Date:  2015-01-10       Impact factor: 1.704

6.  Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report.

Authors:  Seyed-Amir Mirbagheri; Behtash-Ghazi Nezami; Solmaz Assa; Mannan Hajimahmoodi
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

7.  Use of Reticulocyte Hemoglobin Content in the Assessment of Iron Deficiency in Children With Inflammatory Bowel Disease.

Authors:  Sana Syed; Subra Kugathasan; Archana Kumar; Jarod Prince; Bess T Schoen; Courtney McCracken; Thomas R Ziegler; Parminder S Suchdev
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-05       Impact factor: 2.839

8.  Neutrophil-lymphocyte ratio: a controversial marker in predicting Crohn's disease severity.

Authors:  Sheng-Qiang Gao; Li-Dong Huang; Rui-Jie Dai; Dong-Dong Chen; Wei-Jian Hu; Yun-Feng Shan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis.

Authors:  Feng Xie; Gord Blackhouse; Nazila Assasi; Kathryn Gaebel; Diana Robertson; Ron Goeree
Journal:  Cost Eff Resour Alloc       Date:  2009-12-11

10.  Capsule endoscopy in the diagnosis of Crohn's disease.

Authors:  Yaron Niv
Journal:  Med Devices (Auckl)       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.